Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rockwell Medical (RMTI) Gains from Investment Securities (2016 - 2025)

Rockwell Medical (RMTI) has disclosed Gains from Investment Securities for 14 consecutive years, with $124000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Gains from Investment Securities fell 92.74% year-over-year to $124000.0, compared with a TTM value of -$1.5 million through Sep 2025, down 143.83%, and an annual FY2024 reading of $60000.0, changed N/A over the prior year.
  • Gains from Investment Securities was $124000.0 for Q3 2025 at Rockwell Medical, down from $148000.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $1.7 million in Q3 2024 and bottomed at -$1.9 million in Q4 2024.
  • Average Gains from Investment Securities over 5 years is $168062.5, with a median of $129000.0 recorded in 2023.
  • The sharpest move saw Gains from Investment Securities crashed 7060.0% in 2023, then surged 1071.88% in 2024.
  • Year by year, Gains from Investment Securities stood at $150000.0 in 2021, then soared by 303.33% to $605000.0 in 2022, then crashed by 85.12% to $90000.0 in 2023, then plummeted by 2237.78% to -$1.9 million in 2024, then surged by 106.44% to $124000.0 in 2025.
  • Business Quant data shows Gains from Investment Securities for RMTI at $124000.0 in Q3 2025, $148000.0 in Q2 2025, and $146000.0 in Q1 2025.